Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C

Journal of Infection

Volumn 71, Issue 5, 2015, Pages 571-577

  Pineda, Juan A ^a   Núñez Torres, Rocio ^a   Téllez, Francisco ^b   Mancebo, María ^a,c   García, Federico ^d   Merchante, Nicolás ^a,c   Pérez Pérez, Montserrat ^b   Neukam, Karin ^a,c   Macías, Juan ^a,c   Real, Luis M ^a,c  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b Hospital La Línea   (Spain)

^c Instituto de Biomedicina de Sevilla   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Direct acting antivirals; Hepatitis C virus; HIV; Parenteral drug use; Reinfection

Indexed keywords

VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ASSESSMENT; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MOLECULAR PHYLOGENY; REINFECTION; RISK FACTOR; RNA ANALYSIS; VIRAL CLEARANCE; COINFECTION; COMPLICATION; DRUG USE; GENETICS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; PHYLOGENY; PHYSIOLOGY; RECURRENT DISEASE; SPAIN; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG USERS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHYLOGENY; RECURRENCE; RISK FACTORS; RNA, VIRAL; SPAIN;

EID: 84945476047     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.07.006     Document Type: Article

References (30)

1. Grebely J., Prins M., Hellard M.E., Cox A.L., Osburn W.O., Lauer G., et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012, 12:408-414.
2. Grady B.P., Schinkel J., Thomas X.V., Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 2013, 57(Suppl. 2):S105-S110.
3. Mina M.M., Luciani F., Cameron B., Bull R.A., Beard M.R., Booth D., et al. Resistance to hepatitis C virus: potential genetic and immunological determinants. Lancet Infect Dis 2015, 15(4):451-460.
4. Aspinall E.H., Corson S., Doyle J.S., Grebely J., Hutchinson S.H., Dore G.J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013, 57(Suppl. 2):S80-S89.
5. Barrio G., De la Fuente L., Royuela L., Díaz A., Rodríguez-Artalejo F. Cocaine use among heroin users in Spain: the diffusion of crack and cocaine smoking. Spanish Group for the Study on the Route of Administration of Drugs. J Epidemiol Community Health 1998, 52:172-180.
6. Marco A., Esteban J.I., Solé C., da Silva A., Ortiz J., Roget M., et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol 2013, 59:45-51.
7. Grebely J., Knight E., Ngai T., Genoway K.A., Raffa J.D., Storms M., et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 2010, 25:1281-1294.
8. Bate J.P., Colman A.J., Frost P.J., Shaw D.R., Harley H.A.J. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. J Gastroenterol Hepatol 2010, 25:1276-1280.
9. Sacks-Davis R., Aitken C.K., Higgs P., Spelman T., Pedrana A.E., Bowden S., et al. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One 2013, 8:e80216.
10. Grady B.P.X., Vanhommerig J.W., Schinkel J., Weegink C.J., Bruisten S.M., Lindenburg C.E., et al. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. Eur J Gastroenterol Hepatol 2012, 24:1302-1307.
11. Sacks-Davis R., Grebely J., Dore G.J., Osburn W., Cox A.L., Rice T.M., et al. Hepatitis C virus reinfection and spontaneous clearance of reinfection-the InC3 study. J Infect Dis 2015 Apr 15, InC3 Study Group, [Epub ahead of print].
12. Martin T.C.S., Martin N.K., Hickman M., Vickerman P., Page E.E., Everett R., et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 2013, 27:2551-2557.
13. Lambers F.A.E., Prins M., Thomas X., Molenkamp R., Kwa D., Brinkman K., et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011, 25:F21-F27.
14. Ingiliz P., Krznaric I., Stellbrink H.J., Knecht G., Lutz T., Noah C., et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med 2014, 15:355-361.
15. Alestig E., Arnholm B., Eilard A., Lagging M., Nilsson S., Norkrans G., et al. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2011, 11:124.
16. Guelfo J.R., Macias J., Neukam K., Di Lello F.A., Mira J.A., Merchante N., et al. Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment. J Clin Microbiol 2014, 52:4027-4029.
17. Akuta N., Suzuki F., Seko Y., Kawamura Y., Sezaki H., Suzuki Y., et al. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology 2012, 56:2134-2141.
18. Di Lello F.A., Mira J.A., Neukam K., Parra-Sánchez M., Guelfo J.R., Cifuentes C., et al. Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. Arch Virol 2014, 159:3345-3351.
19. Tamura K., Stecher G., Peterson D., Filipski A., Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013, 30:2725-2729.
20. Hill A, Simmons B, Saleem J, Cooke G. Five-year risk of late relapse or reinfection with hepatitis C after sustained virological response: meta-analysis of 49 studies in 8534 patients. In: 22nd Conference on retroviruses and opportunistic infections. Seattle USA, February 23-24, 2015 [Abstract 654].
21. Chen J.Y., Feeney E.R., Chung R.T. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol 2014, 11:362-371.
22. van de Laar T.J.W., Matthews G.V., Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010, 24:1799-1812.
23. Macías J., Palacios R.B., Claro E., Vargas J., Vergara S., Mira J.S., et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int 2008, 28:781-786.
24. Hara K., Rivera M.M., Koh C., Demino M., Page S., Nagabhyru P.R., et al. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?. J Infect Dis 2014, 209:38-45.
25. Blackard J.T., Ma G., Sengupta S., Martin C.M., Powell E.A., Shata M.T., et al. Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV. J Med Virol 2014, 86:1332-1341.
26. Chung R.T. Assessment of efficacy of treatment in HCV: infection and disease. J Hepatol 2006, 44:S56-S59.
27. Vickerman P., Grebely J., Dore G.J., Sacks-Davis R., Page K., Thomas D.L., et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis 2012, 205:1342-1350.
28. Grebely J., Pham S.T., Matthews G.V., Petoumenos K., Bull R.A., Yeung B., et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 2012, 55:1058-1069.
29. Pham S.T., Bull R.A., Bennett J.M., Rawlinson W.D., Dore G.J., Lloyd A.R., et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology 2010, 52:1564-1572.
30. Abdelrahman T., Hughes J., Main J., McLauchlan J., Thursz M., Thomson E. Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. Hepatology 2015, 61:88-97.